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Pretreatment with statins enhances myocardial protection
during coronary revascularization
Harold L. Lazar, MD, Yusheng Bao, MD, Yu Zhang, BS, and Sheilah A. Bernard, MD
Objective: This experimental study was undertaken to determine whether pretreat-
ment with statins would enhance myocardial protection and minimize ischemic
injury during revascularization of acutely ischemic myocardium.
Methods: In 20 pigs the second and third diagonal arteries were occluded for 90
minutes, followed by 45 minutes of blood cardioplegic arrest and 180 minutes of
reperfusion. Ten pigs received atorvastatin (40 mg orally every day) for 21 days
before surgical intervention; 10 others received no statins. Ischemic damage was
assessed on the basis of the need for cardioversions for ventricular arrhythmias,
regional wall-motion scores (4  normal to 1  dyskinesia) were determined by
means of 2-dimensional echocardiography, endothelial function was assessed on the
basis of bradykinin-induced coronary artery relaxation, and infarct size was calcu-
lated by determining the area of necrosis to the area of risk by means of histochem-
ical staining. Results are given as means  SE.
Results: Statin-treated animals required fewer cardioversions (0.11  0.01 vs
2.87  0.20, P  .0001), had improved wall-motion scores (2.81  0.10 vs 1.52 
0.08, P  .01), had lower infarct size (21%  2% vs 41%  2%, P  .0001), and
had more complete coronary artery relaxation (34%  5% vs 8%  4%, P  .01).
Total serum cholesterol levels were similar between the groups (62  5 mg/dL for
statin-treated animals vs 68  5 mg/dL for non–statin-treated animals, P  .30).
Conclusions: Pretreatment with statins enhances myocardial protection during re-
vascularization by means of mechanisms that are independent of their cholesterol-
lowering properties.
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, collec-tively known as statins, have been shown to minimize myocardial ischemicevents in patients with hypercholesterolemia without manifestations ofcardiovascular disease1,2 and in those patients who have already undergonerevascularization procedures, such as coronary artery bypass grafting(CABG) and percutaneous transluminal coronary angioplasty (PTCA).3-5
Hypercholesterolemia results in increased platelet reactivity, endothelial dysfunc-
tion, atherosclerotic plaque formation, and, ultimately, plaque disruption, which
results in acute coronary syndromes. Statins, by lowering serum cholesterol levels,
reduce blood thrombogenicity and improve endothelial function, thereby improving
clinical outcomes. However, recent experimental and clinical studies suggest that
the beneficial effects of statins might extend beyond their ability to reduce serum
cholesterol levels.6-10 In the Myocardial Ischemia Reduction with Aggressive Cho-
lesterol Lowering (MIRACL) trial, high doses of atorvastatin administered to
patients with unstable angina and non–Q-wave myocardial infarction (MI) signifi-
cantly reduced the incidence of recurrent anginal episodes within several weeks.11
Furthermore, at baseline, the low-density lipoprotein (LDL) levels in both groups
were normal (123-125 mg/dL), suggesting that the beneficial effects of statin
therapy might occur in the presence of normal serum cholesterol levels. Recent
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experimental studies in animals subjected to acute ischemic
injury also showed decreased damage with statins in the
presence of normal serum cholesterol.7-10
This experimental study was therefore undertaken to
investigate whether statin therapy might also have a role
during coronary revascularization. Specifically, we sought
to determine whether pretreatment with atorvastatin would
enhance myocardial protection in pigs undergoing surgical
revascularization for acutely ischemic myocardium and
whether the improved outcomes could be correlated with
reductions in serum cholesterol levels.
Methods
Randomization
Twenty adult pigs (35-40 kg) were fed a standard chow diet for 3
weeks. The animals were randomized to statin-treated or non–
statin-treated groups by means of a sealed envelope that assigned
them to receive a 21-day supply of either atorvastatin (40 mg
orally every day) or a placebo. All animals completed the 3-week
pretreatment phase and were entered into the study.
Preparation
The pigs were premedicated with intramuscular injections of ket-
amine (15 mg/kg) and xylazine (0.5 mg/kg), anesthetized with
-chloralose (75 mg/kg), intubated, and placed on positive-pres-
sure ventilation. A mediasternotomy was performed, and the ani-
mals received systemic heparinization (3 mg/kg). The second and
third diagonal coronary arteries just distal to the takeoff of the left
anterior descending artery were occluded with snares for 90 min-
utes. The pigs were then placed on cardiopulmonary bypass, and
the hearts were arrested with multidose, antegrade-retrograde, cold
blood cardioplegia (potassium 25 mEq/L; hematocrit 20%; pH 7.6;
temperature 4°C) supplemented with topical hypothermia for 45
minutes. The aortic crossclamp was then removed, the coronary
snares were released, and all hearts were perfused in normal sinus
rhythm for 180 minutes on cardiopulmonary bypass with a mean
aortic pressure of 60 mm Hg at 37°C.
Experimental Groups
During the 3 weeks before the operation, the animals were divided
into 2 groups. In the non–statin-treated group 10 animals received
only a placebo with their chow. In the statin-treated group 10
animals received atorvastatin, 40 mg orally every day, with their
chow. This dose of atorvastatin has been shown to reduce ischemic
events in clinical studies after an acute MI.11
Measurements and Statistical Analyses
Electrocardiographic leads were placed to measure heart rate. Left
ventricular end-diastolic pressure was recorded with a piezoelec-
tric Mikro-Tip catheter pressure transducer (Millar Instruments
Inc, Houston, Tex) inserted through the left ventricular apex.
Electrical cardioversion was used to treat ventricular fibrillation
and ventricular tachycardia, which was either unresponsive to
intravenous lidocaine or caused a clinically significant (20 mm
Hg) decrease in systolic blood pressure. Serum concentrations of
total cholesterol, LDL cholesterol, high-density lipoprotein cho-
lesterol, and triglycerides were determined by means of standard
enzymatic methods at the Boston Medical Center Central Labora-
tory.
Echocardiographic short- and long-axis sections obtained from
transthoracic echocardiograms were used to define wall-motion
changes in the area of risk, as previously described.12 A wall-
motion score (WMS) was derived (4  normal, 3  mild hypo-
kinesis, 2  moderate hypokinesis, 1  severe hypokinesis, 0 
akinesis, and1 dyskinesia) to indicate changes in wall motion.
The sections were interpreted by an experienced echocardiogra-
pher (S.A.B.) in a blinded fashion, and the scores were averaged
for the coronary occlusion and reperfusion periods for all experi-
mental groups.
Infarct size was assessed by determining the areas of necrosis
to areas of risk by using histochemical staining techniques with
triphenyltetrazolium chloride, as previously described.12 Stained
myocardial slices were planimetered to obtain the area of risk
compared with the total left ventricular mass and the percentage
area of infarction in that area of risk.
Epicardial vascular relaxation was assessed by using standard
organ chamber methodology. A segment of the second or third
diagonal vessel in the area at risk was dissected, cut into rings, and
suspended in organ chambers with oxygenated Krebs buffer at
37°C. Ring tension was determined by using a force-displacement
transducer (Grass Instruments, Inc, West Warwick, RI) attached to
each tensiometer apparatus and recorded on MacLab recording
software. The rings were allowed to equilibrate at a passive tension
of 2 to 3 g for 60 minutes and then contracted with 1 mol/L
prostaglandin F2x and allowed to stabilize. Once a stable contrac-
tion was obtained, coronary vasomotor function was assessed by
generating dose-response curves to cumulative concentrations of
nitroglycerin (109 to 105 mol/L), an endothelial-independent
coronary vasodilator, and the calcium ionophore A23187 and
bradykinin, endothelial-dependent coronary vasodilators. Relax-
ation in response to each concentration of the agonist was calcu-
lated as the percentage reduction in isometric tension from the
tension produced by 1 mol/L prostaglandin F2x. Values were
calculated for each experiment, and mean values were computed
for the various treatment groups.
All pigs received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (National Institutes of Health publication no. 86-23, revised
1985).
All values are presented as means  SE. Nonpaired Student t
tests and Wilcoxon Mann-Whitney tests were used to compare
measured data between the groups. Differences in hemodynamic
measurements between the groups and across time was assessed by
means of repeated measurement analysis of variance. Statview 4.5
(Abacus Concepts, Inc, Berkeley, Calif) was used to compute these
analyses.
Results
Lipid Profiles
The lipid profiles between the statin-treated and non–statin-
treated groups are summarized in Table 1. After 3 weeks of
statin therapy, there was no difference in total cholesterol,
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LDL, high-density lipoprotein, and triglyceride levels be-
tween the groups.
Hemodynamics and Ventricular Irritability During
Coronary Occlusion Before Cardiopulmonary Bypass
Table 2 summarizes the hemodynamics and ventricular
irritability during the 90 minutes of coronary occlusion
before the initiation of cardiopulmonary bypass. Heart rate
remained stable in both groups during the period of coro-
nary occlusion. However, mean arterial pressures were
lower and left ventricular end-diastolic pressures were
higher in both groups compared with preocclusion values.
Mean aortic pressure was statistically lower in the statin-
treated animals after 90 minutes of coronary occlusion
(55 2 vs 62 7 mm Hg, P .03). The need for electrical
cardioversions for ventricular arrhythmias was much higher
in the non–statin-treated animals (2.87  0.20 vs 0.11 
0.01, P  .0001).
Wall-Motion Scores
WMSs are summarized in Figure 1. Both groups had de-
creased wall motion after 90 minutes of coronary occlusion.
However, on reperfusion, WMSs were higher in the statin-
treated animals (2.65  0.08 vs 1.55  0.10 at 60 minutes,
P  .01; 2.81  0.10 vs 1.52  0.08 at 180 minutes, P 
.01).
Coronary Artery Relaxation
Figure 2 summarizes endothelial function, as assessed by
means of coronary artery relaxation. Endothelial-indepen-
dent coronary vasodilation in response to nitroglycerin re-
mained intact in both groups (82% 9% for the non–statin-
treated group vs 95%  7% for the statin-treated group).
Endothelial-dependent vasodilation to both A23187 and
bradykinin was markedly decreased in non–statin-treated
animals. Statin-treated animals showed better recovery of
endothelial-dependent relaxation to both A23187 (20% 
10% for non–statin-treated animals vs 47% 6% for statin-
treated animals, P  .02) and bradykinin (8%  4% for
non–statin-treated animals vs 34%  5% for statin-treated
animals, P  .01).
Infarct Size
The area at risk for necrosis was similar in both groups
(15.5%  3.5% for statin-treated animals vs 18.5%  2.3%
for non–statin-treated animals). However, the area of necro-
sis within the area of risk was lower in statin-treated animals
(21%  2% vs 41%  2%, P  .0001).
Discussion
Our study has showed that pretreatment with atorvastatin
enhances myocardial protection during surgical revascular-
ization of acutely ischemic myocardium. These beneficial
effects occurred in the absence of clinically significant
changes in serum cholesterol levels from nontreated ani-
mals, suggesting that alternative mechanisms might be re-
sponsible for this enhanced myocardial protection. There
are several mechanisms by which statins might decrease
ischemia-reperfusion injury. These include improved endo-
thelial function, a decreased propensity for platelet throm-
bus formation, and reductions in the inflammatory process.
Nitric oxide (NO) production and its degradation regulates
the processes that are responsible for the preservation of
endothelial function. Statins are intimately involved with
several pathways that can affect NO availability. Statins
decrease endothelial cell superoxide production, which in-
activates NO. This occurs not only by reducing LDL but by
directly preventing the isoprenylation of P21 rac, a protein
involved in the formation of the superoxide precursor nic-
otinamide adenine dinucleotide phosphate oxidase.13 Statins
also upregulate the expression of endothelial NO synthase.10
NO synthase activity is inhibited by the protein caveolin 1,
which is inhibited by atorvastatin, thus increasing NO syn-
thase activity.14 It had been thought that it would take
months for these favorable effects on endothelial function to
occur. However, statin therapy has been shown to improve
flow-mediated brachial artery vasodilatation in clinical stud-
ies after only 4 weeks.15 By preserving endothelial function,
statins might decrease platelet adhesion and the stimulation
of plasminogen activator inhibitor, which results in in-
creased thrombogenicity and contributes to ischemic dam-
age during acute coronary syndromes.
Recent experimental studies support the hypothesis that
statins exert their anti-ischemic effects in the absence of
changes in serum cholesterol and independently preserve
endothelial function. Lefer and colleagues9 studied the ef-
fects of simvastatin administered 18 hours before 20 min-
utes of ischemia in isolated normocholesterolemic rat
hearts. Simvastatin improved left ventricular function, in-
creased coronary blood flow, and endothelial NO produc-
tion, and significantly reduced leukocyte accumulation in
the ischemic myocardium. P-selectin expression and CD18
upregulation were attenuated, and the number of leukocytes
adherent to the vascular endothelium was markedly de-
creased. Hence another mechanism for the cardioprotective
effects of statins might be related to their ability to inhibit
leukocytes from adhering to the endothelium. Similar find-
TABLE 1. Lipid profiles
Variable
No statin
(n  10)
Statin
(n  10) P value
Total cholesterol (mg/dL) 68 5 62 5 .30
LDL 38 5 31 3 .14
HDL 31 3 27 3 .50
Triglycerides 42 5 32 10 .32
All values are presented as means  SE. HDL, High-density lipoprotein.
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ings were reported by Weber and associates16 in a clinical
study of patients with hypercholesterolemia. Lovastatin de-
creased CD11b-dependent adhesion of monocytes to human
endothelium in patients independent of its cholesterol-low-
ering effects.
Statins generate mevalonate, a precursor that ultimately
regulates the production of interleukin 8 (IL-8) and the
proinflammatory cytokine IL-6. This ability of statins to
reduce cell adhesiveness contributes to its reduction of
ischemic events. Statins also contribute to reductions in
ischemia-reperfusion injury by decreasing the inflammatory
response associated with acute coronary syndromes. In the
Pravastatin Inflammation C-Reactive Protein Evaluation
study, patients treated with pravastatin after an MI or un-
stable angina had decreased levels of the inflammatory
marker C-reactive protein.6 This effect occurred after only
12 weeks of therapy and was independent of changes in
LDL levels.
The beneficial effects of statins in reducing ischemia-
reperfusion injury are not limited to the myocardium. En-
dres and coworkers8 studied the affects of statins in normo-
cholesterolemic mice subjected to 2 hours of middle
cerebral artery occlusion. Animals pretreated for 14 days
with simvastatin had a reduction in cerebral infarct size by
46% and an increase in cerebral blood flow by 31%. When
animals were pretreated for only 3 days, the reduction in
infarct size was decreased. Lower concentrations of simva-
statin and the use of lovastatin were less effective. The
decrease in infarct size was accompanied by the upregula-
tion of endothelial NO synthase, which was independent of
changes in serum cholesterol. The beneficial effects of sim-
vastatin were absent in endothelial NO synthase–deficient
Figure 1. WMSs are higher in the statin-treated animals after reperfusion.
TABLE 2. Heart rate, mean aortic pressure, left ventricular end-diastolic pressure, and ventricular irritability after 90
minutes of coronary occlusion
Variable
No Statin
(n  10)
Statin
(n  10)
Heart rate (beats/min)
Preocclusion 115 6 111 7
90 min of occlusion 112 7 110 6
Mean arterial pressure (mm Hg)
Preocclusion 74 4 72 6
90 min of occlusion 62 7* 55 2*†
Left ventricular end-diastolic pressure
Pressure (mm Hg)
Preocclusion 4.3 1.1 5.0 1.3
90 min of occlusion 9.0 1.0* 8.6 3.3*
No. of cardioversions 2.87 0.20 0.11 .01‡
All values are presented as means  SE.
*P  .05 from preocclusion values.
†P  .05 from non–statin-treated group.
‡P  .0001 from non–statin-treated group.
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mice. The favorable effects of statins were also seen in
normocholesterolemic rats with angiotensin II–induced hy-
pertension.7 Cerivastatin decreased hypertension, cardiac
hypertrophy, and fibrosis, suggesting that statins might also
decrease AT1 receptor expression independent of their cho-
lesterol-lowering properties.
The results of this experimental study suggest that pre-
treatment with statins might play an important role in re-
ducing ischemia-reperfusion damage during coronary revas-
cularization. However, in a recent clinical study, Florens
and colleagues17 found no effect of atorvastatin in patients
undergoing cardiac surgical procedures. In this study pa-
tients undergoing elective CABG and valve operations were
given 40 mg of atorvastatin in the evening before and 40 mg
the morning of the operation. All patients had normal serum
cholesterol levels. There was no difference in clinical out-
comes or in the expression of levels of inflammatory mark-
ers, such as CD11b, IL-6, IL-8, and P-selectin. There are,
however, several explanations for the failure to observe any
favorable effects of statin therapy in these patients. As noted
by Endres and associates8 in his study on cerebral infarcts in
mice, longer periods of statin therapy might be needed to
see a reduction in ischemia-reperfusion injury. Furthermore,
higher dosages might also be necessary. The MIRACL trial
used 80 mg of atorvastatin for a 70-kg patient.4 The doses
used in our own protocol for 35-kg animals were based on
those used in the MIRACL trial. Hence the absence of any
improvement in the study by Florens and colleagues17 might
have been due to the short duration of therapy and the lower
dose of the statin. In contrast, evidence for the clinical role
of statin pretreatment before coronary revascularization was
seen by Chan and coworkers18 in a retrospective study
involving 5052 patients undergoing PTCA. In this series
26.5% of patients received statin therapy before their
PTCA. Patients receiving statin therapy at the time of their
PTCA had a significant reduction in mortality, which per-
sisted for up to 6 months.
Our results suggest that statin therapy might offer addi-
tional protection to patients during coronary revasculariza-
tion. However, several questions remain to be answered.
How long will pretreatment with statin therapy be neces-
sary, and can lower doses achieve the same anti-ischemic
effects? Will all statin agents be equally effective in pro-
viding cardioprotection for surgical patients? These ques-
tions will need to be answered before conducting clinical
trials and will be the focus of our future studies.
We thank Ms Ellie LaBombard and Ms Deborah Blackman for
their assistance in preparing this manuscript.
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Discussion
Dr Henry M. Spotnitz (New York, NY). Do you want to
speculate on what this might represent, and can you comment on
whether there were any hemodynamic changes, heart rate changes,
or any other ancillary differences you saw that might be involved
in this?
Dr Lazar. During the 90-minute period of coronary occlusion,
there were no significant hemodynamic changes. All the animals
showed slightly decreased blood pressure, more so in the atorva-
statin group than the others, but end-diastolic pressure was about
the same. The mechanism can be divided into 3 properties that
statins are known to have.
The first is improved endothelial function by enhanced stimu-
lation of NO.
The second is decreased platelet thrombogenicity. Statins have
been known, independent of their cholesterol-lowering effects, to
have a favorable effect on P-selectin expression and CD18 expres-
sion, so that it is less likely for platelets to adhere to the arterial
surface.
The third has to do with the inflammatory response. Statins
have been shown in clinical studies after infarcts in patients
undergoing bypass surgery to decrease C-reactive protein.
Dr Frank W. Sellke (Boston, Mass). Do you think 3 weeks is
necessary? Could you give 2 days and get the same effect?
Dr Lazar. As you know, Phillipe Menasche´ did a clinical study
in elective patients undergoing bypass surgery in which he gave
his patients 40 mg of atorvastatin the night before the operation
and 40 mg on the way to the operating room and found absolutely
no change in any of the inflammatory markers. I think the reason
for that is 2-fold.
First, he was looking at patients undergoing elective CABG, in
which you would not expect to see much of a difference with any
intervention. The second reason involves the dose and the timing.
We have some data now to show that 1 week of 40 mg of
atorvastatin in this model has no therapeutic effect, but at 2 weeks
with this same dose, there is a significant reduction in infarct size.
Therefore, I would think that even at 10 days we might be able to
see a beneficial effect.
The second question is, how much do you have to give? We
gave 40 mg to a 30-kg animal, which would be the same as giving
80 mg to a 70-kg person, which is what was done in the MIRACL
trial, a trial that showed improvement in patients receiving ator-
vastatin after an acute MI.
Therefore, I think this really needs to be worked out, but my
feeling would be you do need to use higher doses, and you
probably would have to treat them for anywhere between a week
to 10 days.
Dr Sellke. All these patients should be receiving some sort of
statin drug. If the primary care physicians and cardiologists were
doing their job, this would not have as much clinical relevance, but
it certainly does.
Dr Lazar. That is exactly right. All these patients who are at
risk should be receiving a statin, regardless of their cholesterol
level, and that includes the postoperative period. If they are taking
a statin and we know that we are going to be doing an operation,
they should stay on it and perhaps their dosage should be in-
creased.
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